receptor

(redirected from antigen receptor)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia.
Related to antigen receptor: monoclonal antibody
See: receiver
Mentioned in ?
References in periodicals archive ?
The nucleus-translocated NFAT can bind to upstream response elements of genetic transducing modules to initiate gene expression of chimeric antigen receptor (CAR) for the recognition and killing of target cancer cells.
NK cells engineered with chimeric antigen receptors can be targeted to tumors with high specificity.
DelveInsight Report, "Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016" emphasizes on the currently active CAR-T cell products in research and development.
Riviere, "The basic principles of chimeric antigen receptor design," Cancer Discovery, vol.
The alliance was formalized through an exclusive research and licensing agreement to further study and commercialize novel cellular immunotherapies using chimeric antigen receptor (CAR) technologies.
Eventually they targeted DARC (Duffy Antigen Receptor for Chemokines) which appeared to be less active in mice with higher bone density.
The technique utilizes a genetically engineered antigen receptor, which is applied into cultured human T cells and infused with the T cells in mice that bear widespread tumor cells.
B-cell activation by cross-linking the B-cell antigen receptor, CD40-CD40L interactions to promote switching, TGF-bd1 by directing the switch to IgA, and Th2-type cytokines by increasing the number of post-switch Ig[A.
Altor has already successfully improved and converted the licensed TCRs into targeted therapeutic reagents using its Soluble T-cell Antigen Receptor (STAR[TM]) technology.
The deal underscores the value inherent in Sorrento's proprietary non-viral chimeric antigen receptor technology that may fundamentally alter the way that CAR constructs can be integrated into T cells, Selvaraju tells investors in a research note.
This duality provides CAR NK cells with the unique potential to overcome antigen escape and address tumour heterogeneity, which are distinct advantages over patient-specific chimeric antigen receptor T-cell immunotherapies.
In August 2017, Kymriah became the first available chimeric antigen receptor T cell (CAR-T) therapy when it received FDA approval five weeks prior to its PDUFA date and was launched for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice.